“…[14][15][16][17] In this context that two-drug regimens (2-DR) were approved in the USA and Europe for the treatment of virologically suppressed or treatment naïve patients. 18 Biktarvy has been recommended as the first-line antiretroviral (ARV) therapy for HIV-1-infected patients in Taiwan since October 2019. However, very few studies have investigated the efficacy and safety of BIC/FTC/TAF in Asian populations or in viremic patients who switch to BIC/ FTC/TAF.…”